For radiopharmaceuticals, regulatory approval is only the beginning of value realization.The development of Pluvicto shows that whether a radiopharmaceutical can truly reach patients depends not only ...
A high-quality clinical research network often begins with a leading site that combines access to patients, technical capabilities, and extensive research experience.Consider the team led by Professor...
The momentum behind radiopharmaceuticals is not being driven by a handful of major transactions alone.A field once viewed as niche, complex, and capital-intensive is now being reassessed as a precisio...
